1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
New Leaf Ventures Inc

New Leaf Ventures Inc

NLV.CN
New Leaf Ventures IncCA flagCanadian Securities Exchange
0.05
CAD
- -
- -
1.49MMarket Cap
New Leaf Ventures Inc
NLV.CN
(Canadian Securities Exchange)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
TTM
FRC
- -
- -
0.37
0.25
0.11
0.06
Revenue per Share
- -
-0.19
-1.18
-0.4
-0.2
-0.26
Basic EPS, GAAP
- -
-0.09
-0.56
-0.3
-0.02
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.08
-0.13
0.04
-0.13
-0.12
Book Value per Share
- -
-0.07
-0.08
0.13
-0.08
-0.1
Tangible Book Value per Share
- -
6
6
10
18
24
Basic Weighted Avg Shares
- -
- -
2
2
2
1
Sales/Revenue/Turnover
- -
- -
-127.81
-192.38
-196.87
-358.79
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-7
-4
-4
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-321.8
-160.29
-177.67
-426.98
Profit Margin (%)
- -
- -
-1
- -
- -
-2
Working Capital
- -
- -
3
3
2
2
LT Debt
- -
- -
- -
1
-1
-2
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
29
30
Market Capitalization
3
2
2

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
4
4
4
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
5
6
Payables & Accruals
3
3
4
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-203.63%
Free Cash Flow
- -
- -
-88.2%
Net Income, GAAP
- -
- -
-11.2%
Sales/Revenue/Turnover
- -
- -
-19.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
1
1
1
1
2
2022
1
1
- -
- -
2
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.2
-0.08
-0.09
- -
-0.4
2022
0.02
0.01
0.01
- -
-0.2
2023
-0.05
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Teyi Pharmaceutical Group Co.,Ltd (002728.SZ)
Legacy Technology Holdings, Inc. (LTHO)
LIWANLI Innovation Co., Ltd. (3054.TW)
The Hash Corporation (REZN.CN)
Takeda Pharmaceutical Company Limited (TAK)
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS)
Business
New Leaf Ventures Inc. New Leaf Ventures Inc. (CSE:NLV) operates as a management group focused on evaluating, financing, and accelerating advanced-stage cannabis operations across North America, providing structured capital, consulting services, real property leasing, intellectual property licensing, equipment leasing, and ancillary management support to licensed processors; its flagship operations through New Leaf USA subsidiaries center on a Washington-based Tier 3 processor handling processing, packaging, marketing, and distribution of ultra-premium cannabis and cannabis-related products under brands including DAMA and Goodies, with emphasis on wellness sector growth and multi-state operational integration. The company, founded in 2018 and headquartered in Vancouver, Canada, targets undercapitalized ventures in the cannabis industry, offering scalable financing and applied management to achieve earnings growth while expanding into mature markets in Canada and the United States. In recent developments, New Leaf Ventures completed the acquisition of High Profile Holdings Corp. via a statutory three-cornered amalgamation, integrating High Profile's premium cultivated cannabis products, genetic library, retail activations, and seasoned team to accelerate Canadian market entry, enhance its house of brands, and leverage operational synergies as of the transaction closure following the 2022 definitive agreement.